Program Compounds Sample Clauses

Program Compounds. Within [***] business days of the end of each calendar quarter (ending each March 31, June 30, September 30 and December 31) during the Research Term ARCHEMIX will notify EYETECH and the JRC of each Program Compound identified in such calendar quarter.
Sample 1Sample 2
AutoNDA by SimpleDocs
Program Compounds. Amgen shall pay Tularik the following amounts within [**] after the occurrence of the corresponding milestone events. Each payment under this Section 8.3.1 shall be made only once per Target, for the first Program Compound directed against each particular Program Target (or the first Back-Up Compound directed against such Program Target) for which such milestone is achieved, except as provided below. Milestone Payment [**] [**] Commencement of first Phase I Study [**] Start of first Phase IIB Study [**] Commencement of first Phase IIIA Study [**] First NDA filing [**] First Commercial Sale in Europe [**] First Commercial Sale in the United States [**] First Commercial Sale in Japan [**] [**]
Sample 1
Program Compounds. Notwithstanding the exclusion of one or more indications from the Field for the Tier 1 Program, the Tier 2 Program or any Tier 3 Program (each, an “Excluded Indication”), if, prior to the third (3rd) anniversary of the Amendment Date, Roche proposes to grant to any Third Party any license or other right to develop or commercialize any Program Compound for the Tier 1 Program, the Tier 2 Program or any Tier 3 Program for any Excluded Indication in the Territory, or for any indication outside the Field in the Territory, then, promptly after reaching agreement in principle with such Third Party regarding the material terms upon which Roche would grant such license or right (the “Third Party Terms”) but before entering into any definitive agreement with such Third Party, Roche shall notify Synosia in writing of the Third Party Terms. During the sixty (60)-day period following Xxxxxxx’s receipt of the Third Party Terms, Roche shall, and it hereby does, grant to Synosia an exclusive right of first refusal to obtain such license or right on the Third Party Terms. If Synosia wishes to exercise such right of first refusal, then upon Synosia’s written notification to Roche given at any time prior to the expiration of such sixty (60)-day period, the parties shall use their best efforts to enter into a definitive agreement on the Third Party Terms as promptly as practicable thereafter. If Synosia fails to exercise its right of first refusal by the expiration of such sixty (60)-day period, or if Synosia exercises such right but the parties fail to enter into a definitive agreement within four (4) months after such exercise, then Roche shall be free to grant such license or right to the Third Party on terms no more favorable to such Third Party than the Third Party Terms. In addition, if, on or after the third (3rd) anniversary of the Amendment Date and prior to the sixth (6th) anniversary of the Amendment Date, Roche proposes to grant any license or other right to develop or commercialize, any Program Compound for the Tier 1 Program, the Tier 2 Program or any Tier 3 Program for any Excluded Indication in the Territory, then Roche shall, prior to initiating negotiations with such Third Party with respect thereto, provide written notice of such intent to Synosia, which notice shall identify the applicable Program Compound and Excluded Indication(s) for which Roche proposes to grant such rights. During the sixty (60)-day period following the date Roche delivers such notice...
Sample 1

Related to Program Compounds

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • Research Program The term “Research Program” shall mean the research program to be undertaken by TSRI under the direction and control of the Principal Investigator as expressly set forth on Exhibit A hereto.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Commercialization Diligence Upon receipt of the Marketing Authorization for a Licensed Product in the Field in a given Region in the Territory, Lian (directly, or through its Affiliates, Sublicensees or contractors) will use Commercially Reasonable Efforts to Commercialize such Licensed Product in the Field in such Region in the Territory. Lian will have sole decision-making authority and discretion with respect to Commercializing the Licensed Product in the Field in the Territory. [***].

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

  • Development Program A. Development Activities to be Undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Product The term “

  • Research Program Term The Research Program shall be conducted during the period of five years commencing as of the Agreement Date ("Research Program Term"). Upon not later than seventy-five (75) days' prior written notice JT may, in its sole judgment, terminate the Research Program at the end of the third (3/rd/) year and fourth (4/th/) year of the Research Program. The RMC may terminate the Research Program any time during the Research Program Term if it unanimously determines the Research Program is no longer scientifically useful or that all potential Products would not be commercially viable. In case of such an early termination by JT or the RMC, JT shall be exempt from any payment(s) under Section 10(a) that would have become due and payable after the effective date of such early termination. Following any termination of the Research Program (i) that occurs simultaneously with the termination of this Agreement in accordance with Section 13 (i.e., no compound or Lead Compound has been designated previously a Collaboration Lead Compound in accordance with Section 3(b) and no Independent Lead Compound is being developed in accordance with Section 3(m)) or (ii) that is followed at some future date by the termination by JT of Development or co-promotion of any Collaboration Lead Compound and/or Product pursuant to Sections 3(l) or 5(c), respectively, or development of an Independent Lead Compound in accordance with Section 3(m) (A) any licenses granted by Tularik to JT will terminate, (B) JT will grant to Tularik an exclusive, sublicensable, worldwide license, to make, use and sell compounds, Collaboration Lead Compounds or Products under JT's interest in Program Patents and Program Know-How and (C) under the terms and conditions to be separately agreed, JT will also grant to Tularik a nonexclusive, sublicensable, worldwide license under any JT Patent Rights and Know-How to the extent necessary to practice the license granted under the Program Patents and Program Know-How in (B) (including, with respect to compounds, a limited number of JT's library compounds approved by JT); provided, however, that in the event the Research Program terminates but the Agreement has not terminated with respect to designated Collaboration Lead Compounds, Independent Lead Compounds and/or Products as provided in Section 2(g)(ii), Sections 2(g)(A), (B) and (C) shall apply only to those compounds, Collaboration Lead Compounds, Independent Lead Compounds and Products for which Development or co-promotion shall have been terminated and/or to those compounds or Lead Compounds that have not been designated previously a Collaboration Lead Compound in accordance with Section 3(b) or an Independent Lead Compound in accordance with Section 3(m); provided further that in the event that JT elects to pursue a Discontinued Compound or a Non-Proposed Compound on or before the first anniversary of the expiration or termination of the Research Program Term pursuant to Section 3(b)(iii) or 3(b)(iv), respectively, Sections 2(g)(A), (B) and (C) shall not apply to such Discontinued Compound or Non-Proposed Compound until such time as JT shall have terminated the Development or co-promotion of such Discontinued Compound or Non- Proposed Compound. Tularik will then be free to pursue clinical development and registration of such compounds, Lead Compounds and/or Products without obligation to JT except as provided in Section 4(f) or Section 5(c), as appropriate.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!